铁死亡在卵巢癌中的研究进展

doi:10.12280/gjfckx.20220884

摘要/Abstract

摘要：

铁死亡是一种不同于自噬、凋亡和坏死的新型细胞死亡方式，通过细胞铁过载和脂质过氧化启动。近年来，越来越多的研究探索铁死亡相关机制在卵巢癌中的作用，发现改变卵巢癌细胞内铁和脂质的代谢，以及P53、Yes相关蛋白（Yes-associated protein，YAP）和基于PDZ结合基序的转录共激活因子（transcriptional co-activator with PDZ-binding motif，TAZ）的表达可以调控癌细胞铁死亡，进而影响卵巢癌进展。研究还证实铁死亡不仅可以提高卵巢癌细胞对铂类药物的敏感性，增强化疗效果，而且可以改善卵巢癌细胞对多腺苷二磷酸核糖聚合酶[poly (ADP-ribose) polymerase，PARP]抑制剂的耐药性，提高卵巢癌患者PARP抑制剂治疗的临床获益，而PARP抑制剂与免疫治疗又能促进卵巢癌细胞铁死亡，表明铁死亡与化疗、PARP抑制剂和免疫治疗在抑制卵巢癌细胞生长方面具有协同作用，铁死亡可能成为未来卵巢癌治疗的一个新靶点。

关键词: 铁死亡, 卵巢肿瘤, 药物疗法, 药物耐受性, 多（ADP核糖）聚合酶抑制剂, 免疫疗法

Abstract:

Ferroptosis is a novel cell death mode different from autophagy, apoptosis and necrosis, which is initiated by cellluar iron overload and lipid peroxidation. In recent years, an increasing number studies have explored the role of ferroptosis related mechanisms in ovarian cancer, and found that altered the metabolism of iron and lipid in ovarian cancer cells, as well as the expression of P53, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) can regulate the ferroptosis of cancer cells, thereby delaying the progression of ovarian cancer. Studies also confirmed that ferroptosis can not only improve the sensitivity of ovarian cancer cells to platinum drugs, enhance the effect of chemotherapy, but also improve the resistance of ovarian cancer cells to poly (ADP-ribose) polymerase (PARP) inhibitors, and improve the clinical benefits of PARP inhibitor treatment in ovarian cancer patients, PARP inhibitor and immunotherapy can promote the ferroptosis of ovarian cancer cells in the treatment of ovarian cancer. This shows that ferroptosis and chemotherapy, PARP inhibitors and immunotherapy have synergistic effects in inhibiting the growth of ovarian cancer cells. Therefore, ferroptosis may become a new target for the treatment of ovarian cancer in the future.

Key words: Ferroptosis, Ovarian neoplasms, Chemotherapy, Drug tolerance, Poly (ADP-ribose) polymerase inhibitors, Immunotherapy

齐琦, 张静, 王敏, 林志明, 许飞雪. 铁死亡在卵巢癌中的研究进展[J]. 国际妇产科学杂志, 2023, 50(2): 206-210.

QI Qi, ZHANG Jing, WANG Min, LIN Zhi-ming, XU Fei-xue. Research Progress of Ferroptosis in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 206-210.

参考文献 30

[1]	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5):1060-1072. doi: 10.1016/j.cell.2012.03.042. doi: 10.1016/j.cell.2012.03.042 pmid: 22632970
[2]	Chen X, Yu C, Kang R, et al. Iron Metabolism in Ferroptosis[J]. Front Cell Dev Biol, 2020, 8:590226. doi: 10.3389/fcell.2020.590226. doi: 10.3389/fcell.2020.590226
[3]	Bai Y, Meng L, Han L, et al. Lipid storage and lipophagy regulates ferroptosis[J]. Biochem Biophys Res Commun, 2019, 508(4):997-1003. doi: 10.1016/j.bbrc.2018.12.039. doi: 10.1016/j.bbrc.2018.12.039
[4]	Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal[J]. Oxid Med Cell Longev, 2014, 2014:360438. doi: 10.1155/2014/360438. doi: 10.1155/2014/360438
[5]	Tang D, Kroemer G. Ferroptosis[J]. Curr Biol, 2020, 30(21):R1292-R1297. doi: 10.1016/j.cub.2020.09.068. doi: 10.1016/j.cub.2020.09.068
[6]	Qiu Y, Cao Y, Cao W, et al. The Application of Ferroptosis in Diseases[J]. Pharmacol Res, 2020, 159:104919. doi: 10.1016/j.phrs.2020.104919. doi: 10.1016/j.phrs.2020.104919
[7]	Zhou B, Liu J, Kang R, et al. Ferroptosis is a type of autophagy-dependent cell death[J]. Semin Cancer Biol, 2020, 66:89-100. doi: 10.1016/j.semcancer.2019.03.002. doi: S1044-579X(19)30006-9 pmid: 30880243
[8]	Xia X, Fan X, Zhao M, et al. The Relationship between Ferroptosis and Tumors: A Novel Landscape for Therapeutic Approach[J]. Curr Gene Ther, 2019, 19(2):117-124. doi: 10.2174/1566523219666190628152137. doi: 10.2174/1566523219666190628152137 pmid: 31264548
[9]	Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer[J]. Oncogene, 2017, 36(29):4089-4099. doi: 10.1038/onc.2017.11. doi: 10.1038/onc.2017.11 pmid: 28319068
[10]	Tesfay L, Paul BT, Konstorum A, et al. Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death[J]. Cancer Res, 2019, 79(20):5355-5366. doi: 10.1158/0008-5472.CAN-19-0369. doi: 10.1158/0008-5472.CAN-19-0369 pmid: 31270077
[11]	Xuan Y, Wang H, Yung MM, et al. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells[J]. Theranostics, 2022, 12(7):3534-3552. doi: 10.7150/thno.70194. doi: 10.7150/thno.70194 pmid: 35547771
[12]	Zou Y, Henry WS, Ricq EL, et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion[J]. Nature, 2020, 585(7826):603-608. doi: 10.1038/s41586-020-2732-8. doi: 10.1038/s41586-020-2732-8
[13]	Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network[J]. Free Radic Biol Med, 2019, 133:162-168. doi: 10.1016/j.freeradbiomed.2018.05.074. doi: 10.1016/j.freeradbiomed.2018.05.074
[14]	Liu J, Zhang C, Wang J, et al. The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway[J]. Int J Mol Sci, 2020, 21(21):8387. doi: 10.3390/ijms21218387. doi: 10.3390/ijms21218387
[15]	Zhang Y, Xia M, Zhou Z, et al. p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated with Human Serum Incubated-Superparamagnetic Iron Oxides[J]. Int J Nanomedicine, 2021, 16:283-296. doi: 10.2147/IJN.S282489. doi: 10.2147/IJN.S282489
[16]	Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer[J]. Cancer Cell, 2016, 29(6):783-803. doi: 10.1016/j.ccell.2016.05.005. doi: S1535-6108(16)30210-0 pmid: 27300434
[17]	Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine[J]. Nat Rev Drug Discov, 2020, 19(7):480-494. doi: 10.1038/s41573-020-0070-z. doi: 10.1038/s41573-020-0070-z pmid: 32555376
[18]	Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling[J]. Nature, 2019, 572(7769):402-406. doi: 10.1038/s41586-019-1426-6. doi: 10.1038/s41586-019-1426-6
[19]	Yang WH, Lin CC, Wu J, et al. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2[J]. Mol Cancer Res, 2021, 19(6):1005-1014. doi: 10.1158/1541-7786.MCR-20-0534. doi: 10.1158/1541-7786.MCR-20-0534
[20]	Yang WH, Huang Z, Wu J, et al. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer[J]. Mol Cancer Res, 2020, 18(1):79-90. doi: 10.1158/1541-7786.MCR-19-0691. doi: 10.1158/1541-7786.MCR-19-0691
[21]	Zhu P, Tan MJ, Huang RL, et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors[J]. Cancer Cell, 2011, 19(3):401-415. doi: 10.1016/j.ccr.2011.01.018. doi: 10.1016/j.ccr.2011.01.018 pmid: 21397862
[22]	Fukai T, Ushio-Fukai M. Cross-Talk between NADPH Oxidase and Mitochondria: Role in ROS Signaling and Angiogenesis[J]. Cells, 2020, 9(8):1849. doi: 10.3390/cells9081849. doi: 10.3390/cells9081849
[23]	Li HW, Liu MB, Jiang X, et al. GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway[J]. Future Oncol, 2022, 18(2):149-161. doi: 10.2217/fon-2021-0883. doi: 10.2217/fon-2021-0883
[24]	Cheng Q, Bao L, Li M, et al. Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo[J]. J Obstet Gynaecol Res, 2021, 47(7):2481-2491. doi: 10.1111/jog.14779. doi: 10.1111/jog.14779
[25]	Wang Y, Zhao G, Condello S, et al. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis[J]. Cancer Res, 2021, 81(2):384-399. doi: 10.1158/0008-5472.CAN-20-1488. doi: 10.1158/0008-5472.CAN-20-1488 pmid: 33172933
[26]	Chan DW, Yung MM, Chan YS, et al. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis[J]. Pharmacol Res, 2020, 161:105157. doi: 10.1016/j.phrs.2020.105157. doi: 10.1016/j.phrs.2020.105157
[27]	Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer[J]. Redox Biol, 2021, 42:101928. doi: 10.1016/j.redox.2021.101928. doi: 10.1016/j.redox.2021.101928
[28]	Gasimli K, Raab M, Tahmasbi Rad M, et al. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification[J]. Int J Mol Sci, 2022, 23(18):10892. doi: 10.3390/ijms231810892. doi: 10.3390/ijms231810892
[29]	Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328):328rv4. doi: 10.1126/scitranslmed.aad7118. doi: 10.1126/scitranslmed
[30]	Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569(7755):270-274. doi: 10.1038/s41586-019-1170-y. doi: 10.1038/s41586-019-1170-y